With the rise of precision oncology, genomic profiling is playing a larger role in clinical decision-making, helping bring clarity to targeted treatment approaches. Across all advanced solid tumors, the Oncomap™ test can help when you need faster answers.
The Oncomap test bolsters shared decision-making with detailed, fast results.
Fast, actionable insights help bring clarity to treatment options
The Oncomap test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 7 days*† to help guide timely treatment decisions, usually before the next follow-up visit.
Using next-generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the test identifies clinically relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with ≥15% tumor content,* about the size of a grain of rice. Fewer quantity not sufficient (QNS) samples mean more of your patients get tested and treated quickly.
See how to order a testWhy choose the Oncomap test?
The Oncomap test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.
-
257 genes (SNVs, CNVs, fusions, and structural variants)
-
IO signatures, including tumor mutational burden (TMB) and microsatellite instability (MSI)
-
24 immunohistochemistry (IHC) stains, including PD-L1 (SP142, 22C3)
-
Results reported within 7 days*†
-
>99% sensitivity and specificity,‡ even on samples as small as 3 mm2 with ≥15% tumor content*
100+ therapies
45+ combination therapies
650+ clinical trials
Reports to help take immediate action
Results are provided in an easy-to-interpret report that links actionable biomarkers to current therapy guidelines to help guide treatment options. The report also includes potential evidence-based therapies and clinical trials, delivering treatment options for a breadth of solid tumor types.
The Oncomap test profiles a wide range of genetic structures with test markers
-
Single nucleotide variants (SNVs) and insertions/deletions (indels) in coding regions of the genes listed below
-
Copy number variants
-
Select fusions involving ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6)
-
Untranslated regions and splice junctions when actionable, (eg, MET exon 14 skipping and EGFRvIII)
-
Microsatellite instability (MSI)
-
Tumor mutational burden (TMB)
-
257 Gene NGS Panel
-
Single IHC Stains and Tumor-Specific IHC Panels
|
257 Gene NGS Panel
|
||||||||||
|
ABCB1
ABCC1 ABCC2 ABL1 ACVR1 ACVR1B ACVR2A ACVR2B ACVRL1 ADAMTS1 ADAMTS6 ADAMTS9 ADAMTS16 ADAMTS18 ADAMTSL1 AKT1 AKT2 AKT3 ALK AMER1 APC APLNR AR ARAF |
AREG
ARID1A ARID1B ARID2 ATM ATR ATRX AURKA AURKB AXIN1 AXL B2M BAP1 BARD1 BCOR BMP6 BMPR1A BMPR1B BNIP3 BRAF BRCA1 BRCA2 BRIP1 BTK |
BUB1B
CALR CBL CCND1 CCND2 CCND3 CCNE1 CD274 CDA CDC73 CDH1 CDK4 CDK6 CDK12 CDKN2A CHEK1 CHEK2 CHFR CHKA CIC CREBBP CSF1R CTLA4 CTNNB1 |
CYP19A1
CYP1A1 CYP2D6 CYP3A4 CYSLTR2 DCK DDR2 DICER1 DNMT3A EGFR EMSY EP300 EPCAM EPHA5 EPHA7 ERBB2 ERBB3 ERBB4 ERCC1 ERCC2 ERCC3 ERRFI1 ESR1 ESR2 |
EWSR1
EZH2 FAM175A FANCA FANCC FANCD2 FANCE FANCF FANCG FANCM FAT1 FBXW7 FCGR2A FGD4 FGF3 FGF4 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FLT4 FOXL2 FUBP1 |
GAS6
GATA3 GLI1 GNA11 GNAQ GNAS GSTP1 HAMP HDAC2 HGF HNF1A HRAS HSD3B1 IDH1 IDH2 IGF1R IKZF1 IL6R JAK1 JAK2 JAK3 KDM5C KDM6A KDR |
KEAP1
KIT KRAS MAF MAP2K1 MAP2K2 MAP3K1 MAPK1 MAPK3 MAPKAPK5 MDM2 MDM4 MED12 MEN1 MET MGMT MLH1 MPL MRE11A MSH2 MSH6 MTHFR MTOR MUTYH |
MYC
MYCN MYOD1 NBN NF1 NF2 NFE2L2 NOTCH1 NOTCH2 NOTCH3 NPMI NRAS NTRK1 NTRK2 NTRK3 PALB2 PBRM1 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG |
PIK3R1
PIM1 PLCB4 PLCG1 PMS2 POLD1 POLE PP2R1A PTCH1 PTEN PTPN11 RAD50 RAD51C RAD51D RAF1 RB1 RBM10 RECQL RET RHEB RICTOR RIT1 RNF43 ROS1 |
RPTOR
RRMI SDHB SDHC SETD2 SF3B1 SMAD1 SMAD2 SMAD4 SMAD5 SMAD9 SMARCA4 SMARCB1 SMO SOCS1 SPOP STAG2 STAT3 STAT5A STAT5B STK11 SUFU TERT-p TGFB1 |
TGFB2
TGFB2 TGFB3 TGFBR1 TGFBR2 TNFA1P3 TNK1 TOP2A TP53 TSC1 TSC2 TSHR TYMS VEGFA VHL WTI XRCC1 YES1 |
Bolded genes include fusion detection
| Immunohistochemitry (IHC) | |||
| Single IHC Stains | Tumor Specific Panels | ||
|
ALK
AR CAIX ER hENTI HER2 IDO MET MGMT PD1 |
PD-L1 (22C3)
PD-L1 (SP142) PR PTEN ROS1 TOP1 TP TRKpan TS TUBB3 |
Anal: PD-L1 (22C3), MMR*
Appendix: HER2, PTEN, MMR* Bladder: PD-L1 (22C3), PD-L1 (SP142), MMR* Breast: AR, PD-L1 (22C3), MMR* Previously tested for HER2/ER/PR. Otherwise HER2, ER, PR, PD-L1 (22C3), MSH6, PMS2. Cervical: PD-L1 (22C3), ER, MMR* Cholanglocarinoma: HER2, PD-L1 (22C3), MMR* CNS/Brain: MGMT, CAIX, MMR* Colorectal: HER2, PTEN, MMR* Esophagus: HER2, PD-L1 (22C3), MMR* Gallbladder: HER2, PD-L1 (22C3), ER, MMR* Gastric: HER2, PD-L1 (22C3), MMR* Head and Neck, Salivary Gland: HER2, AR, MMR* Head and Neck, Squamous: PD-L1 (22C3), TUBB3, MMR* Hepatocellular: HER2, PD-L1 (22C3), MMR* Kidney: PD-L1 (22C3), MET, MMR* |
Melanoma: PD-L1 (22C3), PTEN, MMR*
Mesothelioma: PD-L1 (22C3), TS, MMR* Neuroendocrine: PD-L1 (22C3), PTEN, MMR* NSCLC: PD-L1 (22C3), PD-L1 (SP142), ALK, MSH6, PMS2 Ovarian: ER, HER2, MMR* Pancreatic: MMR*, PTEN, hENT1 Penile Cancer: PD-L1 (22C3), MMR* Prostate: AR, PD-L1 (22C3), MMR* Skin, Non-melanoma: PD-L1 (22C3), MMR* Small Bowel: HER2, PTEN, MMR* Soft Tissue: MMR* Testicular: PD-L1 (22C3), MMR* Thymus: PD-L1 (22C3), TUBB3, MMR* Thyroid: PD-L1 (22C3), ALK, MMR* Uterine: ER, HER2, MMR* Vulvar: PD-L1 (22C3), ER, MMR* Other Solid Tumors: PD-L1 (22C3), HER2, MMR* |
| *MMR Panel | |||
| MLH1 MSH2 |
MSH6 PMS2 |
||
-
References
Coverage and financial assistance
Exact Sciences is committed to supporting patient access to the Oncomap test to help your patients make informed decisions about their treatment.